Trader_hao

Analysis on Moderna (Vaccine Company)

Long
NASDAQ:MRNA   Moderna, Inc
Moderna ( MRNA ) is developing a COVID-19 vaccine candidate that is widely considered one of the frontrunners to bring a vaccine to market; it was the first company to share data about how its experimental vaccine performed in a Phase 1 clinical trial. It has so far soared more than 350% since the start of the year. The main reason is that there has been tremendous widespread investor interest on their vaccination project, and the obvious unmet need/opportunity for a COVID-19 vaccine. However, J.P. Morgan just recently downgraded the rating on Moderna ( MRNA ) and signal that its currently overvalued. I feel that if the price dips or there's any pullback, would be a good opportunity to enter for a short hold and probably selling it upon the next peak which I believe would be around their Phase 3 trials. Because long term hold on Moderna might be risky since more often than not, vaccines usually takes a long time before it actually gets released and for the company to be actually profitable.